2009, Number 2
PDF size: 119.38 Kb.
ABSTRACTBackground: Venous thromboembolic disease (VTE) is responsible for at least 10% of deaths in European hospitals, and is the first preventable cause of mortality in hospitalized patients. In Mexico there is a lack of information regarding this problem, the incidence in hospitalized patients could be as high as 60% and it depends on the risk factors and diseases found in each individual. Most importantly is the fact that this figures could be halved with the use of proper prophylaxis. Objectives: Identify the real risk to develop VTE as well as the prophylactic measures applied to hospitalized patients during all their hospital stay. Methods: A case series involving adult patients hospitalized during a 16-day period in February 2008, was conducted. Results: 185 patients were included; mean age was 45 ±17 years with a minimal length of stay of 1 day. One hundred fifty patients were found to have at least one risk factor to develop VTE. According to the 2004 ACCP guidelines, 56 patients were classified in the intermediate risk group, 31 patients in the high risk group and 26 patients in the very high risk group. Prophylaxis was given in only 35.5% of the patients, mainly with non pharmacological measures (48.7%). Conclusions. A reduced utilization of prophylactic antithrombotic measures in hospitalized patients was found. Paradoxically the high risk group was the one with less prophylactic care. We believe, according to this study, that regulatory policies to increase the use of adequate DVT prophylaxis are mandatory.
Rashid et al. Venous thromboprophylaxis in UK medical inpatients. J R Soc Med 2005; 98: 5007-512.
Cohen AT. Presented at the 5th Annual Congress of the European Federation of Internal Medicine; Paris 2005. http://www.prnewswire.co.uk/cgi/news/release?id=153801. Última visita 6-dic-2009.
Tapson VF et al. Venous Thromboembolism prophylaxis in acutely ill hospitalized medical patients: Findings from the international medical prevention registry on venous thromboembolism. Chest 2007; 132(3): 936-45.
Geerts WH et al. Prevention of venous thromboembolism: The seventh ACCP Conference on antithrombotic and thrombolytic therapy ACCP. Chest 2004; 126: 338S-400S.
Deheinzelin et al. Incorrect use of thromboprophylaxis for venous thromboembolism in medical and surgical patients: Results of a multicentric, observational and cross-sectional study in Brazil. Thromb Haemost 2007; 98(4): 756-64.
Levy E, Gabriel S, Dinet J, Rudelli G. Assessing the total cost of management of a patient with deep vein thrombosis (DVT) in France and in Italy. Value in Health 2008; 4(2): 102.
Caprini JA. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value in Health 2003; 6(1): 59-74.
Carrillo ER et al. ¿Hospitales enfermos o pacientes enfermos? Parte II: Profilaxis de la enfermedad tromboembólica venosa en la Fundación Clínica Médica Sur. Med Sur 2007; 14(4): 176-184.
Zaragoza-Delgadillo JC, Sauri-Arce JC, Ochoa-Carrillo FJ, Fuentes-del-Toro S. Prevención de la enfermedad tromboembólica venosa en cirugía. Gac Méd Méx 2007; 143(Supl 1): 35-39.
Villagómez AJ et al. Guías para el Diagnóstico, Prevención y Tratamiento de la Enfermedad Tromboembólica Venosa. Rev Mex Anest 2006; 29(S2): S303-S334.
Dennis RJ et al. Curso clínico y supervivencia en embolia pulmonar: Resultados del Registro Multicéntrico Colombiano (EMEPCO). Acta Med Colomb 2008; 33(3) http://www.scielo.org.co/scielo.php?pid=S0120-24482008000300003&script=sci_arttext. Última visita 9-dic-2009.
Clindiff D. Anticoagulation Therapy for Venous Thromboembolism. Medscape General Medicine 2004; 6(3): 5.